<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03109756</url>
  </required_header>
  <id_info>
    <org_study_id>OV101-16-001</org_study_id>
    <nct_id>NCT03109756</nct_id>
  </id_info>
  <brief_title>Single Dose Pharmacokinetic (PK) Study</brief_title>
  <official_title>A Phase 1 Single Dose PK Study in Adolescent Subjects With Fragile X Syndrome or Angelman Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ovid Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ovid Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial is a Phase 1 Single Dose PK Study in Adolescent Subjects with Fragile X syndrome&#xD;
      (FXS) or Angelman syndrome (AS).&#xD;
&#xD;
        -  The primary objective of the study is to evaluate the pharmacokinetics (PK) of OV101&#xD;
           following a single 5 mg dose of OV101 in adolescents with FXS or AS.&#xD;
&#xD;
        -  Secondary objectives are to determine the safety and tolerability of a single 5 mg dose&#xD;
           of OV101 in adolescents with FXS or AS.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 3, 2017</start_date>
  <completion_date type="Actual">November 28, 2017</completion_date>
  <primary_completion_date type="Actual">November 28, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of maximum plasma concentration achieved following a single dose of OV101</measure>
    <time_frame>10 hours</time_frame>
    <description>Maximum plasma concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of time of maximum plasma concentration following a single dose of OV101</measure>
    <time_frame>10 hours</time_frame>
    <description>Time after administration of drug when maximum plasma concentration is reached (Tmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of plasma half-life following a single dose of OV101</measure>
    <time_frame>10 hours</time_frame>
    <description>Plasma half-life (T1/2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of the area under the plasma concentration versus time curve following a single dose of OV101</measure>
    <time_frame>10 hours</time_frame>
    <description>Area under the curve from 0 to 10 hours (AUC 0-10)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of clearance following a single dose of OV101</measure>
    <time_frame>10 hours</time_frame>
    <description>Total body clearance (CL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of the apparent volume of distribution following a single dose of OV101</measure>
    <time_frame>10 hours</time_frame>
    <description>Apparent volume of distribution during terminal phase (Vz)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety parameters, adverse events, absolute values and changes over time of hematology, clinical chemistry, urinalysis, vital signs, electrocardiogram (ECG)</measure>
    <time_frame>10 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Angelman Syndrome</condition>
  <condition>Fragile X Syndrome</condition>
  <arm_group>
    <arm_group_label>Single-dose 5 mg OV101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OV101</intervention_name>
    <description>Single-dose 5 mg OV101</description>
    <arm_group_label>Single-dose 5 mg OV101</arm_group_label>
    <other_name>Gaboxadol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adolescents with confirmed clinical and previous molecular diagnosis of FXS or AS, age&#xD;
             between 13 to 17 years, inclusive.&#xD;
&#xD;
          2. Subjects must assent to participation in the study (if appropriate), have a parent or&#xD;
             legal guardian/representative capable of providing informed consent on behalf of the&#xD;
             subject, and commit to participate in all assessments described in the protocol.&#xD;
&#xD;
          3. Subjects must be receiving a stable dose of concomitant medications&#xD;
&#xD;
          4. Subjects should be able to complete study assessments.&#xD;
&#xD;
          5. Subjects who are non-sterile must agree to either remain completely abstinent or to&#xD;
             use two effective contraceptive methods from screening until 7 days after the last&#xD;
             dose of study treatment.&#xD;
&#xD;
          6. Subjects must have a parent or other reliable caregiver who agrees to accompany the&#xD;
             subject at all study visits and provide information about the subject as required by&#xD;
             the study protocol, and ensure compliance with the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Inability to swallow a capsule.&#xD;
&#xD;
          2. Poorly controlled seizures&#xD;
&#xD;
          3. Clinically significant abnormal ECG at the time of screening.&#xD;
&#xD;
          4. Positive result on serum or urine pregnancy test for women of child-bearing potential&#xD;
             (have experienced menarche) who are not using a dual method of contraception (e.g.,&#xD;
             condoms plus oral contraceptives), with abstinence being an accepted method.&#xD;
&#xD;
          5. Allergy to gaboxadol or any excipients&#xD;
&#xD;
          6. Concomitant cardiovascular, respiratory, liver, renal, or hematologic diseases of a&#xD;
             degree that would limit participation in the study&#xD;
&#xD;
          7. History of suicidal behavior or considered a high suicidal risk by the investigator.&#xD;
&#xD;
          8. Any medical, psychological, social disorder(s), or other conditions - including&#xD;
             seizure disorder&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ovid Therapeutics Investigative Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ovid Therapeutics Investigative Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>April 6, 2017</study_first_submitted>
  <study_first_submitted_qc>April 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2017</study_first_posted>
  <last_update_submitted>November 29, 2017</last_update_submitted>
  <last_update_submitted_qc>November 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fragile X Syndrome</mesh_term>
    <mesh_term>Angelman Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gaboxadol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

